For decades, pediatric hyperkalemia has been managed largely with non-selective cation-exchange resins, despite limitations in tolerability, palatability, and gastrointestinal safety. This perspective reviews the role of sodium zirconium cyclosilicate (SZC) in children and places the pediatric evidence in the context of broader hyperkalemia management. Current pediatric SZC data remain sparse and are derived from a small retrospective cohort of children with chronic kidney disease (CKD) stages 4-5/5D and an in vitro infant formula pretreatment study. Within those constraints, SZC was associated with potassium reduction in acute and chronic settings, favorable tolerability, stable serum sodium and blood pressure, and high acceptability, which is relevant in pediatrics, where palatability and adherence often determine effectiveness. The available literature also suggests practical pediatric applications, including age-based oral dosing and formula-pretreatment strategies, although no validated weight-based regimen has been established. Beyond potassium lowering, SZC may support a more individualized approach to potassium management in selected children, potentially reducing the need for broad dietary restriction and helping preserve renin-angiotensin-aldosterone system inhibitor therapy when hyperkalemia becomes a limiting factor. However, these broader clinical implications remain preliminary, largely observational, and partly extrapolated from adult data. Accordingly, SZC should not yet be viewed as an established pediatric practice standard, but rather as a promising adjunct for carefully selected patients in whom older resins are poorly tolerated or ongoing hyperkalemia compromises diet quality or cardiorenal therapy. Until prospective pediatric trials better define dosing, safety, and patient-centered outcomes, any off-label use should remain individualized and closely monitored.
Corrêa et al. (Thu,) studied this question.